Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial
Identifieur interne : 003599 ( Main/Exploration ); précédent : 003598; suivant : 003600Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial
Auteurs : Yoshihiro Sato [Japon] ; Jun Iwamoto [Japon] ; Tomohiro Kanoko [Japon] ; Kei Satoh [Japon]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-07.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Calcium.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Alendronate (administration & dosage), Alendronic acid, Amino Acids (urine), Bone Density (drug effects), Bone Resorption (prevention & control), Calcium, Calcium (blood), Drug Therapy, Combination, Ergocalciferol, Ergocalciferols (administration & dosage), Female, Follow-Up Studies, Fracture, Fractures, Spontaneous (prevention & control), Hip, Hip Fractures (prevention & control), Humans, Hypercalcemia, Inorganic element, Nervous system diseases, Osteoporosis, Postmenopausal (prevention & control), Parkinson disease, Parkinson's disease, Prevention, Risk, Vitamin D, Vitamin D Deficiency (prevention & control), alendronate, hip fracture, hypercalcemia, vitamin D.
- MESH :
- chemical , administration & dosage : Alendronate, Ergocalciferols.
- chemical , blood : Calcium.
- chemical , urine : Amino Acids.
- drug effects : Bone Density.
- prevention & control : Bone Resorption, Fractures, Spontaneous, Hip Fractures, Osteoporosis, Postmenopausal, Vitamin D Deficiency.
- Aged, Aged, 80 and over, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Risk.
Abstract
Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization‐induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2‐year follow‐up period was studied. At baseline, both groups of patients had low BMD with high levels of serum‐ionized calcium and urinary deoxypyridinoline (D‐Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10–0.85). The number of hip fracture per 1,000 patient‐years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D‐Pyr levels decreased significantly during the follow‐up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20825
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001073
- to stream Istex, to step Curation: 001073
- to stream Istex, to step Checkpoint: 002060
- to stream PubMed, to step Corpus: 002D32
- to stream PubMed, to step Curation: 002D32
- to stream PubMed, to step Checkpoint: 002E88
- to stream Ncbi, to step Merge: 001599
- to stream Ncbi, to step Curation: 001599
- to stream Ncbi, to step Checkpoint: 001599
- to stream Main, to step Merge: 004914
- to stream PascalFrancis, to step Corpus: 001A92
- to stream PascalFrancis, to step Curation: 001229
- to stream PascalFrancis, to step Checkpoint: 001C44
- to stream Main, to step Merge: 004D39
- to stream Main, to step Curation: 003599
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial</title><author><name sortKey="Sato, Yoshihiro" sort="Sato, Yoshihiro" uniqKey="Sato Y" first="Yoshihiro" last="Sato">Yoshihiro Sato</name></author><author><name sortKey="Iwamoto, Jun" sort="Iwamoto, Jun" uniqKey="Iwamoto J" first="Jun" last="Iwamoto">Jun Iwamoto</name></author><author><name sortKey="Kanoko, Tomohiro" sort="Kanoko, Tomohiro" uniqKey="Kanoko T" first="Tomohiro" last="Kanoko">Tomohiro Kanoko</name></author><author><name sortKey="Satoh, Kei" sort="Satoh, Kei" uniqKey="Satoh K" first="Kei" last="Satoh">Kei Satoh</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B32FD1A39905B841FDF0E6F60A13D417FED9580F</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20825</idno><idno type="url">https://api.istex.fr/document/B32FD1A39905B841FDF0E6F60A13D417FED9580F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001073</idno><idno type="wicri:Area/Istex/Curation">001073</idno><idno type="wicri:Area/Istex/Checkpoint">002060</idno><idno type="wicri:doubleKey">0885-3185:2006:Sato Y:alendronate:and:vitamin</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16538619</idno><idno type="wicri:Area/PubMed/Corpus">002D32</idno><idno type="wicri:Area/PubMed/Curation">002D32</idno><idno type="wicri:Area/PubMed/Checkpoint">002E88</idno><idno type="wicri:Area/Ncbi/Merge">001599</idno><idno type="wicri:Area/Ncbi/Curation">001599</idno><idno type="wicri:Area/Ncbi/Checkpoint">001599</idno><idno type="wicri:doubleKey">0885-3185:2006:Sato Y:alendronate:and:vitamin</idno><idno type="wicri:Area/Main/Merge">004914</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0393852</idno><idno type="wicri:Area/PascalFrancis/Corpus">001A92</idno><idno type="wicri:Area/PascalFrancis/Curation">001229</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001C44</idno><idno type="wicri:doubleKey">0885-3185:2006:Sato Y:alendronate:and:vitamin</idno><idno type="wicri:Area/Main/Merge">004D39</idno><idno type="wicri:Area/Main/Curation">003599</idno><idno type="wicri:Area/Main/Exploration">003599</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial</title><author><name sortKey="Sato, Yoshihiro" sort="Sato, Yoshihiro" uniqKey="Sato Y" first="Yoshihiro" last="Sato">Yoshihiro Sato</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Mitate Hospital, Tagawa</wicri:regionArea><wicri:noRegion>Tagawa</wicri:noRegion></affiliation></author><author><name sortKey="Iwamoto, Jun" sort="Iwamoto, Jun" uniqKey="Iwamoto J" first="Jun" last="Iwamoto">Jun Iwamoto</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Sports Medicine, Keio University School of Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Kanoko, Tomohiro" sort="Kanoko, Tomohiro" uniqKey="Kanoko T" first="Tomohiro" last="Kanoko">Tomohiro Kanoko</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rehabilitation Medicine, Institute of Brain Science, Hirosaki University School of Medicine, Hirosaki</wicri:regionArea><wicri:noRegion>Hirosaki</wicri:noRegion></affiliation></author><author><name sortKey="Satoh, Kei" sort="Satoh, Kei" uniqKey="Satoh K" first="Kei" last="Satoh">Kei Satoh</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Vascular Biology, Institute of Brain Science, Hirosaki University School of Medicine, Hirosaki</wicri:regionArea><wicri:noRegion>Hirosaki</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-07">2006-07</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="924">924</biblScope><biblScope unit="page" to="929">929</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">B32FD1A39905B841FDF0E6F60A13D417FED9580F</idno><idno type="DOI">10.1002/mds.20825</idno><idno type="ArticleID">MDS20825</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Alendronate (administration & dosage)</term><term>Alendronic acid</term><term>Amino Acids (urine)</term><term>Bone Density (drug effects)</term><term>Bone Resorption (prevention & control)</term><term>Calcium</term><term>Calcium (blood)</term><term>Drug Therapy, Combination</term><term>Ergocalciferol</term><term>Ergocalciferols (administration & dosage)</term><term>Female</term><term>Follow-Up Studies</term><term>Fracture</term><term>Fractures, Spontaneous (prevention & control)</term><term>Hip</term><term>Hip Fractures (prevention & control)</term><term>Humans</term><term>Hypercalcemia</term><term>Inorganic element</term><term>Nervous system diseases</term><term>Osteoporosis, Postmenopausal (prevention & control)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Prevention</term><term>Risk</term><term>Vitamin D</term><term>Vitamin D Deficiency (prevention & control)</term><term>alendronate</term><term>hip fracture</term><term>hypercalcemia</term><term>vitamin D</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Alendronate</term><term>Ergocalciferols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Calcium</term></keywords><keywords scheme="MESH" type="chemical" qualifier="urine" xml:lang="en"><term>Amino Acids</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bone Density</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Bone Resorption</term><term>Fractures, Spontaneous</term><term>Hip Fractures</term><term>Osteoporosis, Postmenopausal</term><term>Vitamin D Deficiency</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Drug Therapy, Combination</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Risk</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Acide alendronique</term><term>Calcium</term><term>Elément minéral</term><term>Ergocalciférol</term><term>Fracture</term><term>Hanche</term><term>Hypercalcémie</term><term>Parkinson maladie</term><term>Prévention</term><term>Système nerveux pathologie</term><term>Vitamine D</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Calcium</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization‐induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2‐year follow‐up period was studied. At baseline, both groups of patients had low BMD with high levels of serum‐ionized calcium and urinary deoxypyridinoline (D‐Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10–0.85). The number of hip fracture per 1,000 patient‐years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D‐Pyr levels decreased significantly during the follow‐up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Japon</li></country><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><noRegion><name sortKey="Sato, Yoshihiro" sort="Sato, Yoshihiro" uniqKey="Sato Y" first="Yoshihiro" last="Sato">Yoshihiro Sato</name></noRegion><name sortKey="Iwamoto, Jun" sort="Iwamoto, Jun" uniqKey="Iwamoto J" first="Jun" last="Iwamoto">Jun Iwamoto</name><name sortKey="Kanoko, Tomohiro" sort="Kanoko, Tomohiro" uniqKey="Kanoko T" first="Tomohiro" last="Kanoko">Tomohiro Kanoko</name><name sortKey="Satoh, Kei" sort="Satoh, Kei" uniqKey="Satoh K" first="Kei" last="Satoh">Kei Satoh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003599 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003599 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B32FD1A39905B841FDF0E6F60A13D417FED9580F
|texte= Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial
}}
| This area was generated with Dilib version V0.6.23. |  |